GlassScriptPhysician profile
Sandra Sparks
NPI 1013419225
$3,705.53
in general payments reported to CMS, 2019-2025
25 companies · $678 in 2025
The $678 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $763 · 2022: $742 · 2023: $706 · 2024: $816 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,002.43 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $926.13 | 2021-2025 | Lifevest |
| Medtronic, INC. | $274.24 | 2021-2025 | Linq II |
| Astrazeneca Pharmaceuticals LP | $219.94 | 2021-2024 | Farxiga |
| Atricure, INC. | $181.06 | 2022-2024 | |
| Abiomed | $124.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $107.24 | 2021-2022 | |
| Glaxosmithkline, LLC. | $99.06 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $91.67 | 2024-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $84.63 | 2024-2025 | Watchman Flx, Bodyguardian |
| Pfizer INC. | $78.59 | 2021-2024 | |
| Irhythm Technologies, INC. | $67.40 | 2024 | Zio Monitor, Zio Xt Patch |
| Amarin Pharma, INC. | $52.18 | 2021 | |
| Abbott Laboratories | $42.60 | 2025 | Gallant, Aveir |
| Kiniksa Pharmaceuticals, LTD. | $41.93 | 2023 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $41.57 | 2024 | |
| Merck Sharp & Dohme LLC | $39.42 | 2023 | Verquvo |
| Cardiva Medical, INC. | $38.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.80 | 2021-2023 | Jardiance |
| Daiichi Sankyo INC. | $32.83 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $32.61 | 2025 | |
| Convatec INC. | $32.28 | 2022 | |
| Bard Peripheral Vascular, INC. | $24.08 | 2022 | |
| Amgen INC. | $18.61 | 2023 | Repatha |
| Altathera Pharmaceuticals LLC | $14.27 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Sparks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.